Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Interleukin 2 (Aldesleukin)
Quality of Evidence:
Coadministration has not been studied. A pharmacokinetic interaction with emtricitabine/tenofovir-DF is unlikely as interleukin-2 is mainly eliminated by glomerular filtration. However, tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. If concomitant use of emtricitabine/tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be monitored closely.
Use of emtricitabine/tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic medicinal product like interleukin-2.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking